腎臓がん診断および治療の世界市場レポート 2024

腎臓がん診断および治療の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.2%の年間複合成長率（CAGR）で51億9,000万米ドルに成長すると予想されます。予測期間で予想される成長は、バイオマーカー調査の進歩、ゲノム配列決定の進歩、遠隔医療および遠隔診療の採用増加、精密医療の進歩、迅速診断技術の開発など、さまざまな要因に起因すると考えられます。予測期間中に予想される注目すべき動向には、緩和ケアの統合、長期生存者ケアの拡大、栄養とライフスタイルに焦点を当てた介入、ラジオミクスの役割の増大、リキッドバイオプシーの採用などが含まれます。

予想される腎臓がん罹患率の上昇は、腎臓がん診断および治療市場の拡大の原動力となる見込みです。腎臓がんは、制御不能な増殖と腎皮質腫瘍の形成につながる正常な腎臓細胞の異常な変化を特徴とし、最適な疾患管理のための効果的な診断と治療が必要です。これらのコンポーネントには、早期発見、正確な診断、個別化医療、治療モニタリングなど、いくつかの利点があります。 2023年 3月の米国臨床腫瘍学会（ASCO）によると、2023年には米国で81,800人が腎臓がんと診断され、2020年には世界全体で431,288人に影響が及ぶと推定されています。腎臓がんは、腎臓がん診断および治療市場の成長を促進すると予想されます。

腎臓がん診断および治療市場の拡大は、ヘルスケア費の高騰によって推進されています。ヘルスケア部門に割り当てられる財源の総額を表すヘルスケア支出は、腎臓がん診断および治療のニーズに対処するために非常に重要です。支出の増加により、早期発見、効果的な治療、患者の転帰の向上が保証され、全体的な健康状態の改善と長期的なヘルスケア費の軽減に貢献します。 2023年3月の米国医師会によると、米国のヘルスケア支出は2021年に2.7%増加し、4兆3,000億米ドル、つまり1人当たり1万2,914米ドルに達しました。したがって、ヘルスケア支出の増加が腎臓がん診断および治療市場の主要な促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の腎臓がん診断および治療市場、がんタイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• クリアセルRCC
• 乳頭性RCC
• 嫌色素性細胞RCC
• 尿路上皮がんと移行上皮がん
• 他の種類のがん
• 世界の腎臓がん診断および治療市場、コンポーネント別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 薬物
• 診断
• 世界の腎臓がん診断および治療市場、診断別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 生検
• CTスキャン
• 腎尿管鏡検査
• 静脈性腎盂造影
• 超音波
• 世界の腎臓がん診断および治療市場、治療法別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 標的療法
• 免疫療法
• 化学療法
• 世界の腎臓がん診断および治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 製薬ラボ
• ゲノミクスラボ

第7章 地域および国の分析

• 世界の腎臓がん診断および治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の腎臓がん診断および治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腎臓がん診断および治療市場の競合情勢
• 腎臓がん診断および治療市場の企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck &Co. Inc.
  • Bayer AG
  • Novartis AG

第31章 その他の大手および革新的な企業

• Sanofi SA
• Bristol-Myers Squibb Pharmaceuticals Limited
• Thermo Fisher Scientific Inc.
• AstraZeneca PLC
• Abbott Laboratories
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Co Ltd.
• Amgen Inc.
• Siemens Healthcare GmbH
• Laboratory Corporation of America Holdings
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Illumina Inc.
• PerkinElmer Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Kidney cancer diagnostics and therapeutics encompass methods and treatments utilized for diagnosing and managing kidney cancer, specifically renal cell carcinoma. The primary objectives of these approaches are to detect the presence of kidney cancer, assess its stage and extent, and offer appropriate treatment options to effectively manage the disease.

The main types of kidney cancer include clear cell RCC, papillary RCC, chromophobe RCC, urothelial carcinoma, transitional cell carcinoma, and others. Clear-cell renal cell carcinoma (RCC) is the predominant type, accounting for the majority of kidney cancer cases. RCC is further categorized into various subtypes based on the microscopic appearance of cancer cells. Kidney cancer diagnostics and therapeutics play a crucial role in managing clear cell renal cell carcinoma (RCC), the most prevalent subtype of kidney cancer. Treatment involves the use of components such as drugs and diagnostics, with diagnostics including biopsy, CT scan, nephro-ureteroscopy, intravenous pyelogram, and ultrasound. Therapies for kidney cancer include targeted therapy, immunotherapy, and chemotherapy. The main end-users of these diagnostics and therapeutics are hospitals, pharmaceutical labs, and genomic laboratories.

The kidney cancer diagnostics and therapeutics market research report is one of a series of new reports from The Business Research Company that provides kidney cancer diagnostics and therapeutics market statistics, including kidney cancer diagnostics and therapeutics industry global market size, regional shares, competitors with a kidney cancer diagnostics and therapeutics market share, detailed kidney cancer diagnostics and therapeutics market segments, kidney cancer diagnostics and therapeutics market trends and opportunities, and any further data you may need to thrive in the kidney cancer diagnostics and therapeutics industry. This kidney cancer diagnostics and therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The kidney cancer diagnostics and therapeutics market size has grown strongly in recent years. It will grow from $3.85 billion in 2023 to $4.08 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth observed in the historical period can be attributed to several factors, including advancements in molecular biology research, the progress of clinical trials and drug development, innovations in surgical techniques, discoveries in the field of genetics, and improvements in healthcare access.

The kidney cancer diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to $5.19 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to various factors, including advancements in biomarker research, progress in genomic sequencing, the increased adoption of telemedicine and remote consultations, advancements in precision medicine, and the development of rapid diagnostic technologies. Notable trends expected in the forecast period encompass the integration of palliative care, the expansion of long-term survivorship care, interventions focusing on nutrition and lifestyle, an increased role of radiomics, and the adoption of liquid biopsies.

The anticipated rise in kidney cancer prevalence is poised to be a driving force behind the expansion of the kidney cancer diagnostics and therapeutics market. Kidney cancer, characterized by abnormal changes in normal kidney cells leading to uncontrolled growth and the formation of renal cortical tumors, necessitates effective diagnostics and therapeutics for optimal disease management. These components offer several advantages, including early detection, precise diagnosis, personalized medicine, and treatment monitoring. As per the American Society of Clinical Oncology (ASCO) in March 2023, it is estimated that 81,800 individuals in the United States will be diagnosed with kidney cancer in 2023, with a global impact of 431,288 cases in 2020. Consequently, the increasing prevalence of kidney cancer is expected to foster the growth of the kidney cancer diagnostics and therapeutics market.

The expansion of the kidney cancer diagnostics and therapeutics market is being propelled by the escalation in healthcare spending. Healthcare spending, representing the total financial resources allocated to the healthcare sector, is crucial for addressing the diagnostic and therapeutic needs of kidney cancer. Increased spending ensures early detection, effective treatment, and enhanced patient outcomes, contributing to overall health improvements and mitigating long-term healthcare costs. According to the American Medical Association in March 2023, healthcare spending in the United States witnessed a 2.7% increase in 2021, reaching $4.3 trillion or $12,914 per capita. Thus, the rise in healthcare spending is a key driver of the kidney cancer diagnostics and therapeutics market.

A notable trend gaining traction in the kidney cancer diagnostics and therapeutics market is the approval of innovative products. Major companies in this market are dedicated to developing groundbreaking products to fortify their market positions. For instance, in July 2021, Merck & Co., Inc. secured Health Canada's approval for KEYTRUDA (pembrolizumab) to treat patients with intermediate-high or substantial risk of renal cell carcinoma (RCC) recurrence following nephrectomy. KEYTRUDA, a humanized monoclonal antibody, blocks the programmed death ligand 1 (PD-L1) protein on tumor cells, preventing the immune system from attacking the cancer. This marks a significant advancement in renal cell carcinoma (RCC) treatment, offering benefits such as tumor reduction, slowed cancer growth, and improved quality of life.

Leading companies in the kidney cancer diagnostics and therapeutics market are placing a strong emphasis on the development of innovative products, exemplified by SUTIB, aimed at addressing kidney cancer. SUTIB represents the generic version of Sunitinib, an oral medication recognized for its efficacy in treating certain types of cancer. In a notable example, in February 2021, Glenmark Pharmaceuticals Limited, a prominent pharmaceutical company based in India, successfully launched SUTIB, the generic counterpart of Sunitinib oral capsules, specifically for the treatment of kidney cancer in the Indian market. This introduction is anticipated to provide a more accessible and cost-effective treatment option for patients diagnosed with kidney cancer.

In August 2021, Illumina Inc., a biotechnology company based in the United States, acquired GRAIL for an undisclosed amount. This strategic acquisition aims to expedite the development and commercialization of GRAIL's galleri, a multi-cancer early-detection test, enhancing patient access to life-saving diagnostic services for kidney cancer and other malignancies. GRAIL, a biotechnology company specializing in cancer diagnostics, holds significance for its contribution to early disease detection.

Major companies operating in the kidney cancer diagnostics and therapeutics market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Pharmaceuticals Limited, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Amgen Inc., Siemens Healthcare GmbH, Laboratory Corporation of America Holdings, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Illumina Inc., PerkinElmer Inc., Ipsen S.A, Bio-Rad Laboratories Inc., QIAGEN NV, Exelixis Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health Inc., GeneDx LLC, CD Genomics, Genpath Life Sciences Private Limited

North America was the largest region in the kidney cancer diagnostics and therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney cancer diagnostics and therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the kidney cancer diagnostics and therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The kidney cancer diagnostics and therapeutics market consists of revenues earned by entities by providing kidney cancer diagnostics and therapeutics services such as screening and diagnosis, treatment and therapeutics, radiation therapy, chemotherapy, and surgical interventions services. The market value includes the value of related goods sold by the service provider or included within the service offering. The kidney cancer diagnostics and therapeutics market also includes sales of imaging equipment, biopsy tools, surgical instruments, and supportive care products which are used in providing kidney cancer diagnostics and therapeutics services. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Kidney Cancer Diagnostics And Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on kidney cancer diagnostics and therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for kidney cancer diagnostics and therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kidney cancer diagnostics and therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Cancer Type: Clear Cell RCC; Papillary RCC; Chromophobe RCC; Urothelial Carcinoma And Transitional Cell Carcinoma; Other Cancer Types
• 2) By Component: Drugs; Diagnostics
• 3) By Diagnostics: Biopsy; CT Scan; Nephro-ureteroscopy; Intravenous Pyelogram; Ultrasound
• 4) By Therapy: Targeted Therapy; Immunotherapy; Chemotherapy
• 5) By End-Users: Hospitals; Pharmaceutical Labs; Genomics Laboratories
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Kidney Cancer Diagnostics And Therapeutics Market Characteristics

3. Kidney Cancer Diagnostics And Therapeutics Market Trends And Strategies

4. Kidney Cancer Diagnostics And Therapeutics Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Kidney Cancer Diagnostics And Therapeutics Market Size and Growth

• 5.1. Global Kidney Cancer Diagnostics And Therapeutics Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Kidney Cancer Diagnostics And Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Kidney Cancer Diagnostics And Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Kidney Cancer Diagnostics And Therapeutics Market Segmentation

• 6.1. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Clear Cell RCC
• Papillary RCC
• Chromophobe RCC
• Urothelial Carcinoma And Transitional Cell Carcinoma
• Other Cancer Types
• 6.2. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Drugs
• Diagnostics
• 6.3. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Diagnostics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Biopsy
• CT Scan
• Nephro-ureteroscopy
• Intravenous Pyelogram
• Ultrasound
• 6.4. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Targeted Therapy
• Immunotherapy
• Chemotherapy
• 6.5. Global Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Pharmaceutical Labs
• Genomics Laboratories

7. Kidney Cancer Diagnostics And Therapeutics Market Regional And Country Analysis

• 7.1. Global Kidney Cancer Diagnostics And Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Kidney Cancer Diagnostics And Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market

• 8.1. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Kidney Cancer Diagnostics And Therapeutics Market

• 9.1. China Kidney Cancer Diagnostics And Therapeutics Market Overview
• 9.2. China Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Kidney Cancer Diagnostics And Therapeutics Market

• 10.1. India Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Kidney Cancer Diagnostics And Therapeutics Market

• 11.1. Japan Kidney Cancer Diagnostics And Therapeutics Market Overview
• 11.2. Japan Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Kidney Cancer Diagnostics And Therapeutics Market

• 12.1. Australia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Kidney Cancer Diagnostics And Therapeutics Market

• 13.1. Indonesia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Kidney Cancer Diagnostics And Therapeutics Market

• 14.1. South Korea Kidney Cancer Diagnostics And Therapeutics Market Overview
• 14.2. South Korea Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Kidney Cancer Diagnostics And Therapeutics Market

• 15.1. Western Europe Kidney Cancer Diagnostics And Therapeutics Market Overview
• 15.2. Western Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Kidney Cancer Diagnostics And Therapeutics Market

• 16.1. UK Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Kidney Cancer Diagnostics And Therapeutics Market

• 17.1. Germany Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Kidney Cancer Diagnostics And Therapeutics Market

• 18.1. France Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Kidney Cancer Diagnostics And Therapeutics Market

• 19.1. Italy Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Kidney Cancer Diagnostics And Therapeutics Market

• 20.1. Spain Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market

• 21.1. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market Overview
• 21.2. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Kidney Cancer Diagnostics And Therapeutics Market

• 22.1. Russia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Kidney Cancer Diagnostics And Therapeutics Market

• 23.1. North America Kidney Cancer Diagnostics And Therapeutics Market Overview
• 23.2. North America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Kidney Cancer Diagnostics And Therapeutics Market

• 24.1. USA Kidney Cancer Diagnostics And Therapeutics Market Overview
• 24.2. USA Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Kidney Cancer Diagnostics And Therapeutics Market

• 25.1. Canada Kidney Cancer Diagnostics And Therapeutics Market Overview
• 25.2. Canada Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Kidney Cancer Diagnostics And Therapeutics Market

• 26.1. South America Kidney Cancer Diagnostics And Therapeutics Market Overview
• 26.2. South America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Kidney Cancer Diagnostics And Therapeutics Market

• 27.1. Brazil Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Kidney Cancer Diagnostics And Therapeutics Market

• 28.1. Middle East Kidney Cancer Diagnostics And Therapeutics Market Overview
• 28.2. Middle East Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Kidney Cancer Diagnostics And Therapeutics Market

• 29.1. Africa Kidney Cancer Diagnostics And Therapeutics Market Overview
• 29.2. Africa Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By Component, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Kidney Cancer Diagnostics And Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Kidney Cancer Diagnostics And Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Kidney Cancer Diagnostics And Therapeutics Market Competitive Landscape
• 30.2. Kidney Cancer Diagnostics And Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck & Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bayer AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Kidney Cancer Diagnostics And Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A
• 31.2. Bristol-Myers Squibb Pharmaceuticals Limited
• 31.3. Thermo Fisher Scientific Inc.
• 31.4. AstraZeneca PLC
• 31.5. Abbott Laboratories
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Co Ltd.
• 31.8. Amgen Inc.
• 31.9. Siemens Healthcare GmbH
• 31.10. Laboratory Corporation of America Holdings
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Astellas Pharma Inc.
• 31.13. Eisai Co. Ltd.
• 31.14. Illumina Inc.
• 31.15. PerkinElmer Inc.

32. Global Kidney Cancer Diagnostics And Therapeutics Market Competitive Benchmarking

33. Global Kidney Cancer Diagnostics And Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Kidney Cancer Diagnostics And Therapeutics Market

35. Kidney Cancer Diagnostics And Therapeutics Market Future Outlook and Potential Analysis

• 35.1 Kidney Cancer Diagnostics And Therapeutics Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Kidney Cancer Diagnostics And Therapeutics Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Kidney Cancer Diagnostics And Therapeutics Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer